SciTech Development Announces IRB Approval for Human Clinical Trials
Lead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board ("IRB") approval for its upcoming clinical trials for T-Cell Lymphomas. SciTech Development ("SciTech" or...
ICCA Launches FivePoints Cancer Care to Destroy Late-Stage and Recurrent Tumors without Surgery or Systemic Chemo
FivePoints Cancer Care is a first-ever, comprehensive cancer treatment designed to combine Integrative Cancer Care, Live Cell Tumor Profiling, Tumor-Specific Immunotherapy, and Tumor-Specific Hyperthermia preceding...